Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 21, 2008
The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activitySarah J Schrieber, Zhiming Wen, Manoli Vourvahis, et al.Cancer Chemotherapy and Pharmacology|May 2, 2003
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancerStacy S Shord, Stephanie R Faucette, Heidi H Gillenwater, et al.Journal of Clinical Pharmacology|August 10, 2016
Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human VolunteersGary N Asher, Ying Xie, Ruin Moaddel, et al.Clinical Trials (London, England)|November 8, 2011
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis CK Rajender Reddy, Steven H Belle, Michael W Fried, et al.JAMA|July 17, 2012
Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trialMichael W Fried, Victor J Navarro, Nezam Afdhal, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 18, 2002
The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytesCeleste Lindley, Geraldine Hamilton, Jeannine S McCune, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 15, 2012
The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humansKatarina Ilic, Roy L Hawke, Ranjit K Thirumaran, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 21, 2008
The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African AmericansPatrick J Roberts, Kristan D Rollins, Angela D M Kashuba, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 26, 2011
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis CSarah J Schrieber, Roy L Hawke, Zhiming Wen, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 24, 2007
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluationNina Isoherranen, Shana R Ludington, Raymond C Givens, et al.Pageof 3